Legend Biotech (LEGN) Cash from Financing Activities (2019 - 2025)
Legend Biotech (LEGN) posted Cash from Financing Activities of -$600000.0 for Q4 2025, down 189.55% on a QoQ basis from $670000.0 in Q3 2025, and down 100.0% year-over-year from -$inf billion in Q4 2024.
Legend Biotech (LEGN) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Legend Biotech's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$600000.0 for Q4 2025.
- Quarterly Cash from Financing Activities fell 100.0% year-over-year to -$600000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$253000.0 (down 104.41% YoY) and the FY2025 annual result came in at -$300000.0, down 105.26% from the prior year.
- Cash from Financing Activities was -$600000.0 for Q4 2025 at Legend Biotech, down from $670000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $790.0 million in Q2 2023 and bottomed at -$990000.0 in Q2 2025.
- A 5-year average of $90.1 million and a median of $878000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 78200.1% in 2023, while the deepest fall reached 1876.0% in 2023.
- Legend Biotech's Cash from Financing Activities stood at $323.6 million in 2021, then tumbled by 100.24% to -$783000.0 in 2022, then jumped by 218.14% to $925000.0 in 2023, then slumped by 132.43% to -$300000.0 in 2024, then tumbled by 100.0% to -$600000.0 in 2025.
- Business Quant data shows LEGN's Cash from Financing Activities at -$600000.0 in Q4 2025, $670000.0 in Q3 2025, and -$990000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 238.74 Mn |
| 10 | Legend Biotech | 8.26 Bn | 7.36 Bn | - | -600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -600,000.00 |
| Dec 31, 2025 | -600,000.00 |
| Sep 30, 2025 | 670,000.00 |
| Sep 30, 2025 | 670,000.00 |
| Jun 30, 2025 | -990,000.00 |
| Jun 30, 2025 | -990,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Dec 31, 2024 | -300,000.00 |
| Dec 31, 2024 | -300,000.00 |
| Sep 30, 2024 | 4.25 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 955,000.00 |
| Jun 30, 2024 | 955,000.00 |
| Mar 31, 2024 | 831,000.00 |
| Mar 31, 2024 | 831,000.00 |
| Dec 31, 2023 | 925,000.00 |
| Dec 31, 2023 | 925,000.00 |
| Sep 30, 2023 | 961,000.00 |
| Sep 30, 2023 | 961,000.00 |